In the last reported quarter, Champions Oncology witnessed a negative surprise of 25%.
Shares of the company have surged 46.3% so far this year.
Let’s see how things are shaping up for this quarter to be reported.
Factors at Play
Champions Oncology develops technology solutions and services to customize the development and use of oncology drugs. The company does not have any approved products in its portfolio.
It has two new services, namely Ex Vivo platform and pre-approved Clinical Flow Cytometry. The EX VIVO platform and services enable the company’s large tumor bank to support large screening studies and assist customers with early preclinical work.
Notably, the already launched Ex Vivo services are yielding promising results and the company expects the same from the recently launched Ex Vivo platform as well.
Earlier, on second-quarter fiscal 2019 conference call, Champions Oncology stated that it is focused on expanding its human Clinical Flow Cytometry platform beyond preclinical studies. Back then, management confirmed that it will share some preliminary results on the same over the next two quarters and expect to start generating revenues from Cytometry services only toward the end of the next fiscal year. We expect an update on that front during the upcoming earnings call.
Champions Oncology’s performance over the last three reported quarters has been mixed. The company’s earnings surpassed expectations once, missed on another occasion and fell in line with estimates in another quarter, the average positive surprise being 125.00%.
Our proven model does not conclusively show that Champions Oncology is likely to beat estimates this reporting cycle. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: Champions Oncology has an Earnings ESP of 0.00% as the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 3 cents each. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Champions Oncology currently has a Zacks Rank #5 (Strong Sell). We caution against stocks with a Zacks Rank #4 (Sell) or 5 going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Champions Oncology, Inc. Price and EPS Surprise
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider as our model shows that these have the right combination of elements to beat on earnings this season.
BioDelivery Sciences International Inc. (BDSI – Free Report) is scheduled to report fourth-quarter results on Mar 14. The company has an Earnings ESP of +38.46% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks’ Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn’t you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market’s +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.